Jeanette E. Cueva, M.D.; American Psychiatric Association; Spanish American Medical Society; NYC; Mount Kisco, NY

Curriculum Vitae:
Jeanette Eulalia Cueva, M.D.

EDUCATION

1978 – 1982 B.S. Degree: Fordham University, Bronx, New York. Major in Biology, Minor in Philosophy
1982 – 1986 M.D. Degree: New York Medical College, Valhalla, New York, Medicine

POSTDOCTORAL TRAINING

July 1, 1986 – June 30, 1987 Intern, General Psychiatry (PGY I)
St. Vincent's Hospital and Medical Center, New York, NY
July 1, 1987 – June 30, 1990 Resident, General Psychiatry (PGY II-IV)
St. Vincent's Hospital and Medical Center, New York, NY
July 1, 1990 – June 30, 1991 Resident, Child and Adolescent Psychiatry (PGY V)
St. Vincent's Hospital and Medical Center, New York, NY
July 1, 1991 – June 30, 1992 Chief Resident, Child and Adolescent Psychiatry
(PGY VI), St. Vincent's Hospital and Medical Center, New York, NY
June 29, 1992 – June 28, 1993 Research Fellow (PGY VII)
Research Training in Child Psychopharmacology
National Institute of Mental Health,
Institutional Training Grant (T32 MH 18915)
Director, Magda Campbell, MD
Department of Psychiatry
New York University Medical Center, New York, NY
June 29, 1993 – June 28, 1994 Chief Research Fellow (PGY VIII)
Research Training in Child Psychopharmacology
National Institute of Mental Health,
Institutional Training Grant (T32 MH 18915)
Director, Magda Campbell, MD
Department of Psychiatry
New York University Medical Center, New York, NY
February 1996 – February 1997 Psychoanalytic Psychotherapy
Columbia University, Psychoanalytic Institute
Director, Don Meyers, M.D.
Department of Psychiatry
Columbia University and Medical Center, College of Physicians and Surgeons, New York, NY

LICENSURES

1989 State of New York and Surgical License
1991 New York State Dept. of Health, Bureau of Controlled Substances

SPECIALTY CERTIFICATIONS

1989 Diplomate of the National Board of Examiners
1991 American Board of Psychiatry and Neurology in Psychiatry, Certificate #34563
1993 American Board of Psychiatry and Neurology in Child and Adolescent Psychiatry, Certificate #3212

ACADEMIC APPOINTMENTS

July 1992 – June 1994 Clinical Instructor of Psychiatry, Department of Psychiatry, New York University Medical Center, New York, NY
July 1994 – February 2000 Assistant Professor of Psychiatry, Department of Psychiatry, New York Medical College, Valhalla, NY
March 2000 – August 2002 Associate Professor of Clinical Psychiatry and Behavioral Sciences, Department of Psychiatry, New York Medical College, Valhalla, NY
August 2002 – August 2008 Adjunct Associate Professor of Clinical Psychiatry and Behavioral Sciences, Department of Psychiatry, New York Medical College, Valhalla, NY
August 2002 – Present Associate Clinical Professor of Psychiatry, Department of Psychiatry, Columbia University, College of Physicians and Surgeons, New York, NY

RESEARCH PRACTICE

August 2002 - Present Medical Director of Bioscience Research, LLC

PRIVATE PRACTICE

July 1994 - Present Solo Private Practice in Adult, Adolescent, and Child Psychiatry, Psychopharmacology, and Psychodynamic Psychotherapy

HOSPITAL AND CLINICAL APPOINTMENTS

July 1986 – June 1990 General Psychiatry Resident; Housestaff, St. Vincent's Hospital and Medical Center, New York, NY
July 1990 – June 1991 First Year Child and Adolescent Psychiatry Resident; Housestaff, St. Vincent's Hospital and Medical Center, New York, NY
July 1991 – June 1992 Second Year Child and Adolescent Psychiatry Chief Resident; Housestaff, St. Vincent's Hospital and Medical Center, New York, NY
July 1994 – June 1997 Medical Director, Child Psychiatry Inpatient Service St. Vincent's Hospital and Medical Center, New York, NY
July 1997 – August 2000 Chief, Child and Adolescent Psychiatry Outpatient Service, St. Vincent's Hospital and Medical Center, New York, NY
August 2000 – November 2001 Chief, Child and Adolescent Psychiatry Outpatient Service, St. Vincent's Catholic Medical Centers-Manhattan Region, New York, NY
Nov. 2001 – August 2002 Medical Director, Chief, Child and Adolescent Psychiatry Outpatient Service, St. Vincent's Catholic Medical Centers-Manhattan Region, New York, NY
August 2002 – August 2006 Medical Director, Integrated Mental Health Program in Pediatric Primary Care, Columbia-Presbyterian Division of Child Psychiatry and Pediatrics, New York, NY
August 2006 – Present Attending, Division of Child and Adolescent Psychiatry, Dept. of Psychiatry, New York Presbyterian Hospital, New Your, NY

TEACHING EXPERIENCE

Clinical teaching and supervision of Medical Student in Inpatient and Outpatient General Psychiatry, St. Vincent’s Hospital and Medical Center, New York, NY, July 1986 – June 1990
Clinical teaching and supervision of Medical Students and General Psychiatry Residents in Inpatient and Outpatient Child Psychiatry, St. Vincent’s Hospital and Medical Center, NY, NY, July 1990 – June 1992
Preceptor to second year Medical Students as part of the course entitled Introduction to Psychopathology, New York University School of Medicine, New York, NY, July 1992 – February 1993
Supervision of third and fourth year General Psychiatry Residents; first and second year Child Psychiatry Residents in Outpatient Child Psychiatry, St. Vincent’s Hospital and Medical Center, New York, NY, September 1994 – June 2002
Supervision of first year Child Psychiatry Resident and second year General Psychiatry Resident in Inpatient Child Psychiatry, St. Vincent’s Hospital and Medical Center, New York, NY, September 1994 – June 1997
Research Practicum in Child and Adolescent Psychiatry; Course given to first and second year Child Psychiatry Residents, Department of Psychiatry, St. Vincent’s Hospital and Medical Center, New York, NY, September 1994 – June 2002
Introduction to Child Psychiatry; Course given to third year Medical Students, New York Medical College, Valhalla, NY, September 1994 – February 2000
Mental Retardation and the Pervasive Developmental Disorders; Course given to third year General Psychiatry Residents, St. Vincent’s Hospital and Medical Center, New York, NY, January 1995 – February 2000
Introduction to Behavioral Science; Course given to first year Medical Students, New York Medical College, Valhalla, NY, May 1995 – February 2000;May 2001
Conduct Disorder; Lecture given to first and second year General Psychiatry Residents and Pediatric Residents, Saint Vincent’s Hospital and Medical Center, New York, NY, July 1995 – June 2001
Pediatric Psychopharmacology; Lecture given to second year General Psychiatry Residents, St. Vincent’s Hospital and Medical Center, New York, NY, January 1996 – December 1999
Attention Deficit/Hyperactivity Disorder; Lecture given to first and second year General Psychiatry Residents and Pediatric Residents, St. Vincent’s Hospital and Medical Center, New York, NY, January 1996 – June 2001
Oppositional Defiant Disorder; Lecture given to second year General Psychiatry Residents, St. Vincent’s Hospital and Medical Center, New York, NY, January 1996 – June 2001
Mental Retardation; Lecture given to second year General Psychiatry Residents, St. Vincent’s Hospital and Medical Center, New York, NY, January 1996 – February 2000
Autism and PDD; Lecture given to second and fourth year General Psychiatry Residents and Pediatric Residents, St. Vincent’s Hospital and Medical Center, New York, NY, March 1996 – February 2000
Aggression and Conduct Disorders in Children; Lecture given to Child and Adolescent Psychiatry Residents, New York Hospital-Cornell Medical Center, New York, NY, March 5, 1996
Aggression and Conduct Disorders in Children; Lecture given to fourth year General Psychiatry Residents, St. Vincent’s Hospital and Medical Center, New York, NY, October 1996 – October 2000
Inpatient Child Psychiatry; Lecture given to fourth year General Psychiatry Residents, St. Vincent’s Hospital and Medical Center, New York, NY, October 1996 – October 1999
Conduct Disorder; Lecture given to first year medical students, New York Medical College, Valhalla, NY, May 1997 – Present
Child and Adolescent Psychopharmacology; Course given to first and second year Child and Adolescent Psychiatry Residents, St. Vincent’s Hospital and Medical Center, New York, NY, September 1997 – September 2000
Human Development; Course given to PGY-II General Psychiatry Residents, St. Vincent’s Hospital and Medical Center, New York, NY, November 1997 – December 1999
Attention Deficit Hyperactivity Disorder; Lecture given to first year medical student, New York Medical College, Valhalla, NY, May 31, 2002
Child Abuse; Lecture given to first year medical students, New York Medical College, Valhalla, NY, May 31, 2002
Supervision in Child Psychiatry: of PGY-III General Psychiatry Residents and Child Psychiatry Fellows, New York Presbyterian Hospital, New York, NY Sept 2006 – present

ADMINISTRATIVE APPOINTMENTS

February 2000 – November 2001: Manager, Child and Adolescent Psychiatry Outpatient Service, St. Vincent’s Catholic Medical Centers-Manhattan Region, New York, NY

RESEARCH ACTIVITIES

Research in Adults, Adolescents and Children Psychopharmacology at Saint Vincent’s Hospital and Medical Center in Manhattan and Bellevue Psychiatric Hospital, New York University Medical Center. During training, Brain Imaging Research in Adults with psychotic symptoms; mentorship by Dr. Ralph O’Connell, M.D. (1989-1990) and National Institutes of Mental Health Research Training Fellowship (1992-1994), Program Director Dr. Magda Campbell, M.D., 1992-1994.

Research Investigations (post training): Pharmacotherapy and assessment issues in severely disturbed children, adolescents and adults. Particular areas of research interest include developmental disorders (including autism), disruptive behavior disorders, mood disorders, anxiety disorders, psychotic disorders and women’s mental health.

RESEARCH ACTIVITIES, 1992-1994

1. Double-blind and Placebo Controlled Study of Carbamazepine in Aggressive Children with
Conduct Disorder. Preceptor, Magda Campbell, M.D.
2. Long-term Prospective Study of Haloperidol and Tardive Dyskinesia in Autistic Children. Preceptor, Magda Campbell, M.D.
3. Double-blind and Placebo Controlled Study of Naltrexone in Autistic Children. Preceptor, Magda
Campbell, M.D.
4. Plasma Beta-Endorphin Levels in Autistic Children. Preceptor, Magda Campbell, M.D.
5. Clomipramine in Autistic Children. Preceptor, Magda Campbell, M.D.
6. Molecular and Linkage Genetics in Autism. Preceptor, Magda Campbell, M.D. (Collaborative Study with Roland D. Ciaranello, M.D., Stanford University).

CLINICAL TRIAL RESEARCH GRANTS

1. Population Pharmacokinetic Study in Adolescent Patients with Schizophrenia or Bipolar I Disorder Treated with Olanzapine. Principal Investigator: David Sert Krakow, M.D., Co-Investigator: Jeanette E. Cueva, M.D.; Sponsor: Eli Lilly & Company, February 2000.
2. The Study of Olanzapine plus Fluoxetine in Combination for Treatment-resistant Depression Without Psychotic Features. Principal Investigator: Jeanette E. Cueva, M.D., Co-Investigator: David Sert Krakow, M.D.; Sponsor: Eli Lilly & Company, February 2000.
3. Olanzapine vs. Placebo in the Treatment of Adolescents with Schizophrenia. Principal Investigator: Jeanette E. Cueva, M.D., Co-Investigator: David Sert Krakow, M.D.; Sponsor: Eli Lilly & Company, February 2000.
4. Olanzapine vs. Placebo in the Treatment of Mania in Adolescents with Bipolar I Disorder. Principal Investigator: Jeanette E. Cueva, M.D., Co-Investigator: David Sert Krakow, M.D.; Sponsor: Eli Lilly & Company, February 2001.
5. A Phase III, Randomized, Multi-center, Double-blind, Parallel-group, Placebo-controlled Safety and Efficacy Study of ADDERALL XR® with an Open-label Extension, in the Treatment of Adolescents Aged 13–17 with Attention Deficit Hyperactivity Disorder (ADHD). Principal Investigator: Jeanette E. Cueva, M.D., Co-Investigator: David Sert Krakow, M.D.; Sponsor: Shire Pharmaceutical Development, Inc., February 2001.
6. A comparison of fasting triglyceride levels cohorts with schizophrenic and related disorder treated chronically with Olanzapine, Risperidone and typical anti-psychotics. Principal Investigator: Jeanette E. Cueva, M.D., Co-Investigator: David Sert Krakow, M.D.; Sponsor: Eli Lily & Company; August 2001.
7. Olanzapine vs. Ziprasidone in the treatment of Schizophrenia. Principal Investigator: Jeanette E. Cueva, M.D., Co-Investigator: David Sert Krakow, M.D.; Sponsor: Eli Lily & Company; August 2001.
8. Olanzapine vs. Risperidone in the treatment of Bipolar I disorder, mixed or manic. Principal Investigator: Jeanette E. Cueva, M.D., Co-Investigator: David Sert Krakow, M.D.; Sponsor: Eli Lily & Company; August 2001.
9. The Efficacy and Safety of Risperidone in the treatment of Children and Adolescents with Schizophrenia. Principal Investigator: Jeanette E. Cueva, M.D.; Sponsor: Janssen/Medex; April 2001.
10. A Multi-center, Randomized, Double-blind Study and Tolerability Study of Flexible Doses of Aripiprazole and Olanzapine in the Treatment of Patients with Acute Schizophrenia. Principal Investigator: Jeanette E. Cueva, M.D., Co-Investigator: David Sert Krakow, M.D.; Sponsor: Bristol Myers Squibb; October 2000.
11. A Multi-center, Randomized, Double-blind Study of Flexible Doses of Aripiprazole vs. Perphenazine in the Treatment of Patients with Treatment-Resistant Schizophrenia. Principal Investigator: Jeanette E. Cueva, M.D., Co-Investigator: David Sert Krakow, M.D.; Sponsor: Bristol Myers Squibb; August 2000.
12. Olanzapine Plus Fluoxetine Combination Therapy in Treatment Resistant Depression: A Dosing Range Study. Principal Investigator: Jeanette E. Cueva, M.D., Co-Investigator: David Sert Krakow, M.D.: Sponsor: Eli Lilly and Co.; March 2000.
13. A Double-blind, 12-Month Continuation Protocol for Patients who Successfully Completed Protocol RO548. Principal Investigator: Jeanette E. Cueva, M.D., Co-Investigator: David Sert Krakow, M.D.; Sponsor: Pfizer/Scirex; April 2000.
14. A Double-blind Multi-center Study Comparing The Safety and Efficacy of Ziprasidone to Olanzapine in Patients with Schizophrenia or Schizoaffective Disorder Needing Inpatient Care. Principal Investigator: Jeanette E. Cueva, M.D., Co-Investigator: David Sert Krakow, M.D.; Sponsor: Pfizer/Scirex; April 2000.
15. A Multi-center, 10-Week, Randomized, Double-blind Study of Sertraline and Placebo in Children and Adolescents with Post-traumatic Stress Disorder. Principal Investigator: Jeanette E. Cueva, M.D., Co-Investigator: David Sert Krakow, M.D.; Sponsor: Pfizer Pharmaceuticals Group; January 2003.
16. A Randomized, Double-Blind Comparison of Placebo and Atomoxetine Hydrochloride Given Once a Day in Adults with Attention-Defecit/Hyperactivity Disorder: with a Secondary Examination of Impact of Treatment on Family Functioning. Principal Investigator: David Sert Krakow, M.D., Co-Investigator: Jeanette E. Cueva, M.D.; Sponsor: Eli Lilly & Company; 2004.
17. A Multi-center, Open-label Safety and Tolerability Study of Flexible-Dose Oral Aripiprazole (2mg – 30mg) in the Treatment of Adolescent Patients with Schizophrenia, and Child and Adolescent Patients with Bipolar I Disorder, Manic or Mixed Episode. Principal Investigator: Jeanette E. Cueva, M.D., Co-Investigator: David Sert Krakow, M.D.; Sponsor: Otsuka Maryland Research Institute, Inc., February 2005.
18. A Multi-center, Randomized, Double-blind, Placebo-controlled Study with Two Fixed Oral Doses of Aripiprazole (10mg or 30mg) in the Treatment of Adolescent Patients with Schizophrenia. Principal Investigator: Jeanette E. Cueva, M.D., Co-Investigator: David Sert Krakow, M.D.; Sponsor: Otsuka Maryland Research Institute, Inc., 2005.
19. A Multi-center, Randomized, Double-blind, Placebo-controlled Study of Two Fixed Oral Doses of Aripiprazole (10mg or 30mg) in the Treatment of Child and Adolescent Patients Aged 10–17 Years, with Bipolar I Disorder, Manic or Mixed Episode with or without Psychotic Features. Principal Investigator: Jeanette E. Cueva, M.D., Co-Investigator: David Sert Krakow, M.D.; Sponsor: Otsuka Maryland Research Institute, Inc., February 2005.
20. A Randomized, Multicenter, Double-Blind, Parallel Group Study to Compare the Effects of Bifeprunox and Quetiapine on Weight Changes in Stable Schizophrenia Patients. Principal Investigator: David Sert Krakow, M.D., Co-Investigator: Jeanette E. Cueva, M.D.; Sponsor: Solvay Pharmaceuticals; January 2007.
21. A Multicenter, Randomized, Double-Blind, Placebo and Escitalopram Controlled Trial of the Safety and Efficacy of BMS-562086 in the Treatment of Outpatients with Major Depressive Disorder. Principal Investigator: David Sert Krakow, M.D., Co-Investigator: Jeanette E. Cueva, M.D.; Sponsor: Bristol-Myers Squibb Pharmaceutical Research Institute; March 2007.
22. A Multicenter, Randomized, Double-Blind, Placebo and Escitalopram Controlled Trial of the Safety and Efficacy of Pexacerfont (BMS-562086) in the Treatment of Outpatients with Generalized Anxiety Disorder. Principal Investigator: David Sert Krakow, M.D., Co-Investigator: Jeanette E. Cueva, M.D.; Sponsor: Bristol-Myers Squibb Pharmaceutical Research Institute; July 2007.
23. An Open-Label Study of Tolerability, Safety, and Pharmacokinetics of Duloxetine in the Treatment of Children and Adolescents with Major Depressive Disorder. Principal Investigator: Jeanette E. Cueva, M.D., Co-Investigator: David Sert Krakow, M.D.; Sponsor: Eli Lilly and Company; August 2007.
24. A One Year Open Label Study Assessing the Safety and Tolerability of Vilazodone in Patients with Major Depression Disorder. Principal Investigator: David Krakow, M.D., Co-Investigator: Jeanette Cueva, M.D.; Sponsor: PGx Health; January 2008.
25. A Phase III, Open-label Study of SPD503 in Children and Adolescents aged 6–17 with Attention Deficit Hyperactivity Disorder. Principal Investigator: Jeanette E. Cueva, M.D., Co-Investigator: David Sert Krakow, M.D.; Sponsor: Shire Pharmaceutical Development, Inc., February 2008.
26. A Phase III, Randomized, Multi-center, Double-blind, Parallel-group, Placebo-controlled Safety and Efficacy Study of SPD503 in Children and Adolescents aged 6–17 with Attention Deficit Hyperactivity Disorder. Principal Investigator: Jeanette E. Cueva, M.D., Co-Investigator: David Sert Krakow, M.D.; Sponsor: Shire Pharmaceutical Development, Inc., February 2008.
27. A 12 Week, Randomized, Open-Label Trial of Duloxetine Versus Generic SSRIs in the Treatment of a Severe Depressive Episode. Principal Investigator: David Krakow, M.D., Co-Investigator: Jeanette Cueva, M.D.; Sponsor: Eli Lilly, May 2008.
28. The Evaluation of LAMICTAL™ as an Add-on Treatment for Bipolar I Disorder in Children and Adolescents, 10 to 17 Years of Age. Principal Investigator: Jeanette Cueva, M.D., Co-Investigator: David Krakow, M.D.; Sponsor: GlazoSmithKline, July 2008.
29. A Phase III, Double-Blind, Randomized, Placebo-Controlled, Multi-center, Dose Optimization Study Evaluating the Efficacy and Safety of SPD503 in Combination With Psychostimulants in Children and Adolescents Aged 6-17 With a Diagnosis of ADHD. Principal Investigator: Jeanette Cueva, M.D., Co-Investigator: David Krakow, M.D.; Sponsor: Shire Pharmaceutical Development, Inc., September 2008.
30. A Phase III, Open-Label, Extension, Multi-center, Safety and Efficacy Study of LDX in Adolescents Aged 13-17 with ADHD. Principal Investigator: Jeanette Cueva, M.D., Co-Investigator: David Krakow, M.D.; Sponsor: Shire Pharmaceutical Development, Inc., October 2008.
31. A Phase III, Randomized, Double-Blind, Multi-center, Parallel-Group, Placebo-Controlled, Forced-Dose Titration, Safety and Efficacy Study of LDX in Adolescents Aged 13-17 With ADHD. Principal Investigator: Jeanette Cueva, M.D., Co-Investigator: David Krakow, M.D.; Sponsor: Shire Pharmaceutical Development, Inc., October 2008.
32. A Multi-Center, Randomized, Placebo-Controlled, Double-Blind, Parallel Group, Efficacy and Safety Study of AZDXXXX in the Treatment of Generalized Anxiety Disorder (GAD). Principal Investigator: David Krakow, M.D., Co-Investigator: Jeanette Cueva, M.D.; Sponsor: AstraZeneca, February 2009.
33. A Multicenter, Long-Term, Open-Label Study to Assess the Safety and Tolerability of OPC-XXX as Adjunctive Therapy in the Treatment of Outpatients with Major Depressive Disorder. Principal Investigator: David Krakow, M.D., Co-Investigator: Jeanette Cueva, M.D.; Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc., May 2009.
34. A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of OPC-XXX as Adjunctive Therapy in the Treatment of Patients with Major Depressive Disorder. Principal Investigator: David Krakow, M.D., Co-Investigator: Jeanette Cueva, M.D.; Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc., May 2009.
35. A Randomized, Double-Blind, Placebo- and Active-Controlled, Parallel-Group, Multicenter Study of 3 Dosages of JNJ-XXX in the Treatment of Adult Subjects with Attention-Deficit/Hyperactivity Disorder. Principal Investigator: David Krakow, M.D., Co-Investigator: Jeanette Cueva, M.D.; Sponsor: Johnson & Johnson Pharmaceutical Development & Commercialization, Inc., May 2009.
36. A Double-blind, placebo-controlled study of Cariprazine as adjunctive therapy in Major Depressive Disorder. Principal Investigator: David Krakow, M.D., Co-Investigator: Jeanette Cueva, M.D.; Sponsor: Forest Laboratories, July 2009.
37. A Study to Assess the Long-Term Efficacy and Safety of Olanzapine and Fluoxetine Combination Versus Fluoxetine Only in the Relapse Prevention of Stabilized Patients with Treatment-Resistant Depression. Principal Investigator: David Krakow, M.D., Co-Investigator: Jeanette Cueva, M.D.; Sponsor: Eli Lilly, August 2009.
38. A 12 week, randomized, double-blind, placebo-controlled, phase III safety trial of XXX tablets (100 milligrams daily) in women taking a selective serotonin or serotonin –norepinephrine reuptake inhibitor with decreased sexual desire and distress. Principal Investigator: David Krakow, M.D., Co-Investigator: Jeanette Cueva, M.D.; Sponsor: Boehringer-Ingelheim Pharmaceuticals, March 2010.
39. A Phase 4, randomized, double-blind, multicenter, placebo-controlled, parallel group study evaluating the safety and efficacy of XXX on executive function (self-regulation) behaviors in adults with ADHD reporting clinically significant impairment of real-world executive function behavior. Principal Investigator: David Krakow, M.D., Co-Investigator: Jeanette Cueva, M.D.; Sponsor: Shire Pharmaceutical Development, Inc., April 2010.
40. A Phase III, Placebo-controlled, Long-Term Safety and Tolerability Study of TC-5214 as an Adjunct to an Antidepressant in Patients with Major Depressive Disorder. Principal Investigator: David Sert Krakow, M.D., Co-Investigator: Jeanette E. Cueva, M.D.; Sponsor: AstraZeneca, September 2010.
41. A Long-Term, Open-Label, Safety Study of LY2216684 12 to 18 mg Once Daily as Adjunctive Treatment for Patients with Major Depressive Disorder Who are Partial Responders to SSRI Treatment. Principal Investigator: David Sert Krakow, M.D., Co-Investigator: Jeanette E. Cueva, M.D.; Sponsor: Eli Lilly & Company, October 2010.
42. A Phase III, Placebo-controlled, Efficacy and Safety Study of 3 Fixed Dose Groups of TC-5214 as an Adjunct to an Antidepressant in Patients with Major Depressive Disorder. Principal Investigator: David Sert Krakow, M.D., Co-Investigator: Jeanette E. Cueva, M.D.; Sponsor: AstraZeneca, January 2011.
43. A Phase IIIb, randomized, double blind, placebo-controlled, 13-week clinical trial to assess the efficacy and safety of Duloxetine 30/60 mg QD compared to placebo in adolescents with Juvenile Primary Fibromyalgia Syndrome. Continued efficacy and safety of Duloxetine 30/60 mg QD will be assessed in a 26-week, open-label treatment extension period. Principal Investigator: David Sert Krakow, M.D., Co-Investigator: Jeanette E. Cueva, M.D.; Sponsor: Eli Lilly, May 2011.
44. A Multicenter, Randomized, Double-Blind, Active-Controlled, Comparative Fixed-Dose Response Study of the Efficacy and Safety of BMS-820836 in Patients with Treatment Resistant Major Depression. Principal Investigator: David Sert Krakow, M.D., Co-Investigator: Jeanette E. Cueva, M.D.; Sponsor: Bristol Meyers Squibb, June 2011.
45. A Multicenter, Double-Blind, 58 Week Rollover Study to Assess the Safety and Tolerability of BMS-820836 in Patients with Treatment Resistant Major Depression. Principal Investigator: David Sert Krakow, M.D., Co-Investigator: Jeanette E. Cueva, M.D.; Sponsor: Bristol Meyers Squibb, June 2011.
46. A Multicenter, Randomized, Double-Blind, Placebo controlled, Parallel-Group Study to Evaluate the Efficacy, Safety and Tolerability of Desvenlafaxine Succinate Sustained-Release (DVS SR) in the Treatment of Children and Adolescent Outpatients with Major Depression a Placebo-Controlled, Comparative Fixed-Dose Response Study of the Efficacy and Safety of BMS-820836 in Patients with Treatment Resistant Major Depression. Principal Investigator: Jeanette E. Cueva, M.D. Co- Investigator: David Sert Krakow, M.D.,; Sponsor: Pfizer, June 2011.

MEMBERSHIP ON BOARD OF DIRECTORS

New York Council of Child and Adolescent Psychiatry, May 1995 - 2002

COMMITTEE APPOINTMENTS

Member, Clinical Care Committee, Department of Psychiatry, St. Vincent’s Hospital and Medical Center, New York, NY: July 1987 – June 1988
Founding Member, Management and Resident Liaison Committee, Department of Psychiatry and the House Staff, St. Vincent’s Hospital and Medical Center, New York, NY: July 1988 – June 1989
Member, Management and Resident Liaison Committee, Department of Psychiatry, St. Vincent’s Hospital and Medical Center, New York, NY: July 1989 – June 1990
Member, Utilization Review Committee, Department of Psychiatry, St. Vincent’s Hospital and Medical Center, New York, NY: July 1990 – June 1991
Member, Clinical Care Committee, Department of Psychiatry; Extended Training Committee, Department of Psychiatry; Management and Resident’s Liaison Committee, Department of Psychiatry; Residency Training Committee, Department of Psychiatry; Executive Committee, Department of Psychiatry and Attending Faculty and Service Chiefs Workgroups, Department of Psychiatry, St. Vincent’s Hospital and Medical Center, New York, NY: July 1991 – June 1992
Member, Residency Recruitment Committee, Department of Psychiatry; Clinical Studies Committee, Department of Psychiatry; Child Residency Training Committee, Department of Psychiatry; Medical Staff Work Group, Department of Psychiatry and Administrative Committee, Department of Psychiatry; St. Vincent’s Hospital and Medical Center, New York, NY: July 1994 – August 2002
Member, Research Committee of St. Vincent’s Hospital and Medical Center, New York, NY: January 1996 – August 2002
Faculty Senator at New York Medical College, Valhalla, NY: July 1997 – August 2002
Member, Utilization Review Committee, Department of Psychiatry; Medical Student and Residency Training Committee, Department of Psychiatry, and General Medical Education Committee, St. Vincent’s Hospital and Medical Center, New York, NY: September 1997 – August 2002
Member, Internal Review Board of St. Vincent’s Hospital and Medical Center, New York, NY: July 1999 – August 2002
Member, Clinical Care Committee, Department of Psychiatry, St. Vincent’s Hospital and Medical Center, New York, NY: August 2000 – August 2002

MEMBERSHIP ON ADVISORY BOARD

Pfizer Pharmaceuticals, 1998

REVIEWER FOR SCIENTIFIC JOURNALS

1. Journal of the American Academy of Child and Adolescent Psychiatry, January 1995 – Present
2. Comprehensive Journal of Psychiatry, May 1995

MEMBERSHIP ON SPEAKER PANEL

Pfizer Pharmaceuticals, 1998
Parke-Davis, 1998

MEMBERSHIP IN PROFESSIONAL AND SCIENTIFIC SOCIETIES

American Psychiatric Association, 1988 – Present
Spanish American Medical Society, 1989 – Present
American Academy of Child and Adolescent Psychiatry, 1990 – Present
American Association for the Advancement of Science, 1991 – 1994
World Federation for Mental Health, 1992 – 1995
New York County Medical Society, 1993 – 1995
American Psychopathological Association, 1995-Present
Association of Women Psychiatrists, 1997 – Present
Women’s Medical Association of New York City, 1997 – 2000

HONORS AND AWARDS

Honor al Merito, award presented by Ateneo Ecuatoriano de Nueva York Inc., October 11, 1986
American College of Neuropsychopharmacology (ACNP)/NIMH Minority Travel Award, 1991
Nancy C.A. Roeske, M.D., Certificate of Excellence, presented at the 152nd Annual Meeting of the APA, 1999
Top Doctors of New York Metro-Area, Selected by Castle Connolly Medical Ltd., 2001
Top Doctors of New York Metro-Area, Selected by Castle Connolly Medical Ltd., 2010

DISSERTATION SUPERVISED

Title: An Examination of Attachment, Affective Functioning and Social Information Processing in Children with Conduct Disorder; Institution: Farleigh Dickinson University, Psychology; Candidate: Jeanne Marron; Date: July 1997 – July 1999

DISSERTATION COMMITTEE SERVED ON

PUBLICATIONS IN JOURNALS

1. O'Connell, R, Sereci, Jr, S, Fastov, M, Cueva, JE. Luck, D, Nathanson, M and van Heertum, R. The Role of SPECT Brain Imaging in Assessing Psychopathology in the Medically Ill. General Hospital Psychiatry, 13:305-312, 1991.
2. Shay, J, Sanchez, LE, Cueva, JE, Armenteros, JC, Overall, JE and Campbell, M. Neuroleptic-related Dyskinesias and Stereotypies in Autistic Children: Videotape Ratings. Psychopharmacol. Bulletin, 29(3):359-363, 1993.
3. O'Connell, R, van Heertum, RL, Luck, D, Yudd, AP, Cueva, JE, Billick, SB, Cordon, D, Gersh, RJ and Masdeu, JC. Single-Photon Emission Computed Tomography of the Brain in Acute Mania and Schizophrenia. J.Neuroimaging, 5(2):101-104, 1995.
4. Campbell, M and Cueva, JE. Psychopharmacology in Child and Adolescent Psychiatry: A Review of the Past Seven Years, Part I. J. Amer. Acad. Child Adolesc. Psychiatry, September, 34(9): 1124-1132, 1995.
5. Campbell, M and Cueva, JE. Psychopharmacology in Child and Adolescent Psychiatry: A Review of the Past Seven Years, Part II. J. Amer. Acad. Child Adolesc. Psychiatry, 34 (10); 1262-1272, 1995.
6. Campbell, M, Kafantaris, V and Cueva, JE. An Update on the Use of Lithium Carbonate in Aggressive Children and Adolescents with Conduct Disorders. Psychopharmacol. Bulletin, 31(1); 93-102, 1995.
7. Campbell, M, Schopler, E, Cueva, JE and Hallin, A. Treatment of Autistic Disorder. J. Amer. Acad. Child Adolesc. Psychiatry, 35(2); 134-143, 1996.
8. Sanchez, LE, Campbell, M, Small, AM, Cueva, JE, Armenteros, JL and Adams, PA. A Pilot Study of Clomipramine in Young Autistic Children. J. Amer. Acad. Child Adolesc. Psychiatry, 35(4); 537-544, 1996.
9. Cueva, JE, Overall, JE, Small, AM, Armenteros, JL, Perry, R and Campbell,M. Carbamazepine in Aggressive Children with Conduct Disorder: A Double-Blind and Placebo-Controlled Study. J. Amer. Acad. Child Adolesc. Psychiatry, 35(4), 480-490, 1996.
10. Robb, A, Cueva, JE, Sporn, J, Yang, R and Vanderburg, D. Sertraline Treatment of Children and Adolescents with Posttraumatic Stress Disorder: A Double-Blind, Placebo-Controlled Trial. J. of Child and Adolescent Psychopharmacology, 20(6); j 463-471, 2010.

BOOK CHAPTERS

1. Campbell, M, Cueva, JE and Hallin, A. Autism/Developmental Disorders. In: Diagnosis and Psychopathology of Childhood and Adolescent Disorders; JW Wiener (Ed.), New York, NY: Wiley, pp 151-192, 1996.
2. Campbell, M, Cueva, JE and Adams, PB. Pharmacotherapy of Impulsive-Aggressive Behavior. In: Personality and Psychopathology; CR Cloninger (Ed.), Washington, DC: American Psychiatric Press, pp. 431-455, 1999.

LETTERS TO THE EDITOR

Lykes, WC and Cueva, JE,. Risperidone in Childhood Schizophrenia. J. Amer. Acad. Child Adolesc. Psychiatry, Letter to the Editor, 35(4); pp 405-406, 1996.

ABSTRACTS

1. O'Connell, R, Sereci, Jr. S., Fastov, M, Cueva, JE, Luck, D, Nathanson, M and van Heertum, R. SPECT Brain Imaging in Bipolar Manics. New Research and Abstracts, The 146th Annual Meeting of the American Psychiatric Association, Washington, DC. May 1992.
2. Campbell, M, Sanchez, LE, Shay, J, Cueva, JE, and Armenteros, JL. Tardive Dyskinesia in Children. Abstracts. The 5th Annual New York State Office of Mental Health Research Conference, December 7-9, 1992, NY, p.32.
3. Shay, J, Sanchez, LE, Cueva, JE, Armenteros, JL, Overall, JE and Campbell, M. Neuroleptic- related Dyskinesias and Stereotypies in Autistic Children: Videotape Ratings. Abstracts of Panels and Posters, 31st Annual Meeting of the American College of Neuropsychopharmacology, San Juan, PR December 14-18, 1992, p.188.
4. Cueva, JE, Armenteros, JL, Rosenberg, AM and Campbell, M. Untoward Effects of Carbamazepine in Hospitalized Aggressive Children with Conduct Disorder. Neuropsychopharmacology, First International Congress on Hormones, Brain and Neuropsychopharmacology, Rhodes, Greece, September 15, 1993 vol.9, no. 2S, p. 94s.
5. Armenteros, JL, Cueva, JE, Sanchez, LE, Adams, P and Campbell, M. Early vs. Late Onset Neuroleptic-related Dyskinesias in Autistic Children: Preliminary Findings. Neuropsychopharmacology, First International Congress on Hormones, Brain and Neuropsychopharmacology, Rhodes, Greece, September 15, 1993 vol.9, no. 2S, p. 94s.
6. Cueva, JE, Rosenberg, CR and Campbell, M. Placebo Responders During Baseline as Rated on the Overt Aggression Scale. Scientific Proceedings of the Annual Meeting, 40th Annual Meeting of the American Academy of Child and Adolescent Psychiatry, San Antonio, TX, October 30, 1993, vol. IX, p. 64.
7. Sanchez, LE, Cueva, JE, Armenteros, JL and Campbell, M. Untoward Effects and Their Clinical Management in Young Autistic Children Treated with Clomipramine. New Research Program and Abstracts, 147th Annual Meeting of the American Psychiatric Association, Philadelphia, PA, May 23, 1994, p. 86.
8. Cueva, JE, Campbell, M, Adams, PB and Small, AM. The Overt Aggression Scale: A Useful Instrument for Capturing Aggressiveness. Scientific Proceedings of the Annual Meeting, 41st Annual Meeting of the American Academy of Child and Adolescent Psychiatry, New York, NY, October 29, 1994, p. 71.
9. Sanchez, LE, Cueva, JE, Armenteros, JL and Campbell, M. A Pilot Study of Clomipramine in Hospitalized Autistic Children. Scientific Proceedings of the Annual Meeting, 41st Annual Meeting of the American Academy of Child and Adolescent Psychiatry, New York, NY, October 28, 1994, p. 68.
10. Geller, B, Sverd, J, Frazier, ,Walsh, BT, Liebowitz, M, Greenhill, L and Cueva, JE. Advanced Topics in Psychopharmacology. Scientific Proceedings of the Annual Meeting, 42nd Annual Meeting of the American Academy of Child and Adolescent Psychiatry, New Orleans, LA, October 22, 1995, p. 12.
11. Cueva, JE. Carbamazepine in Children with Aggressive Conduct Disorder. Scientific Proceedings of the Annual Meeting, 42nd Annual Meeting of the American Academy of Child and Adolescent Psychiatry, New Orleans, LA, October 22, 1995, p. 13.
12. Cueva, JE, Marron, J, Rackow, L, Pazur, B, Eth, S. Depakote Rapid Stabilization in Bipolar Adolescents. Scientific Proceedings of the Annual Meeting, 45th Annual Meeting of the American Academy of Child and Adolescent Psychiatry, Anaheim, CA, October 28, 1998, p.99.
13. Hyman, D, Gallagher, T, Cueva, JE, McCord, M. Integrating Mental Health Professionals into Urban, Academic Pediatric Practices. Symposium Series Abstracts, 2005th Annual Meeting of the American Academy of Pediatrics (Peds-21), Washington, DC, October 7, 2005, p 15.
14. Robb, A, Cueva, JE, Sporn, J, Yang, R and Vanderburg, D. Sertraline Treatment of Children and Adolescents with Posttraumatic Stress Disorder: A Double-Blind, Placebo-Controlled Trial. Scientific Proceedings of the Annual Meeting, 56th Annual Meeting of the American Academy of Child and Adolescent Psychiatry, Honolulu, Hawaii October 30, 2008.

PRESENTATIONS AT PROFESSIONAL MEETINGS

1. O'Connell, R, Sereci, Jr. S, Fastov, M, Cueva, JE, Luck, D, Nathanson, M and van Heertum. SPECT Imaging in Bipolar Manics, New Research Programs and Abstracts, 146th Annual Meeting of the American Psychiatric Association, Washington DC, May 3, 1992.
2. Campbell, M, Sanchez, LE, Shay, J, Cueva, JE and Armenteros, J. Tardive Dyskinesia in Children; presented at the Fifth Annual New York State Office of Mental Health Research Conference, Albany, NY, December 7-9. 1992.
3. Shay, J, Sanchez, LE, Cueva, JE, Armenteros, J, Overall, JE and Campbell, M. Neuroleptic-related Dyskinesias and Stereotypies in Autistic Children: Videotape Ratings; presented at the 31st Annual Meeting of the American College of Neuropsychopharmacology, San Juan, PR, December 14-18, 1992.
4. Cueva, JE, Armenteros, JL, Rosenberg, AM and Campbell, M. Untoward Effects of Carbamazepine in Hospitalized Aggressive Children with Conduct Disorder; presented at the First International Congress on Hormones, Brain and Neuropsychopharmacology, Rhodes, Greece, September 13-17, 1993.
5. Armenteros, JL, Cueva, JE, Sanchez, LE, Adams, P and Campbell, M. Early vs. Late Onset Neuroleptic-related Dyskinesias in Autistic Children: Preliminary Findings; presented at the First International Congress on Hormones, Brain and Neuropsychopharmacology, Rhodes, Greece, September 13-17, 1993.
6. Cueva, JE, Rosenberg, CR and Campbell, M. Placebo Responders During Baseline as Rated on the Overt Aggression Scale; presented at the 40th Annual Meeting of the American Academy of Child and Adolescent Psychiatry, San Antonio, TX, October 26-31, 1993.
7. Adams, P, Sanchez, LE, Cueva, JE, Armenteros, JL, Small, AM and Campbell, M. Adverse Psychological Influences and Response to Psychoactive Agents in Aggressive Children with Conduct Disorder; presented at the Annual Meeting of the American Psychopathological Association, New York, NY, March, 1994.
8. Sanchez, LE, Cueva, JE, Armenteros, JL and Campbell, M. Untoward Effects and Their Clinical Management in Young Autistic Children Treated with Clomipramine; presented at the 147th Annual Meeting of the American Psychiatric Association, Philadelphia, PA, May 21-26, 1994.
9. Cueva, JE. Rett Syndrome and Its Variants: Recent Progress; presented at Recent Advances in Child and Adolescent Neuropsychiatric Research. University of Goteborg, Sweden, May 16-17, 1994.
10. Cueva, JE, Campbell, M, Adams, PB and Small, AM. The Overt Aggression Scale: A Useful Instrument for Capturing Aggressiveness; presented at the 41st Annual Meeting of the American Academy of Child and Adolescent Psychiatry, New York, NY, October 25-30, 1994.
11. Sanchez, LE, Cueva, JE, Armenteros, JL and Campbell, M. A Pilot Study of Clomipramine in Hospitalized Autistic Children; presented at the 41st Annual Meeting of the American Academy of Child and Adolescent Psychiatry, New York, NY, October 25-30, 1994.
12. Cueva, JE. Carbamazepine in Aggressive Children with Conduct Disorder; presented at the 42nd Annual Meeting of the American Academy of Child and Adolescent Psychiatry, New Orleans, LA, October 22, 1995.
13. Cueva, JE, Marron, J, Rackow, L, Pazur, B, Eth, S.Depakote Rapid Stabilization in Bipolar Adolescents. Scientific Proceedings of the Annual Meeting; presented 45th Annual Meeting of the American Academy of Child and Adolescent Psychiatry, Anaheim, CA, October 28, 1998.
14. Robb, A, Cueva, JE, Sporn, J, Yang, R and Vanderburg, D. Efficacy of Sertraline in Childhood Posttraumatic Stress Disorder: A Double-Blind, Placebo-Controlled Trial. Presented at the 56th Annual Meeting of the American Academy of Child and Adolescent Psychiatry, Honolulu, Hawaii October 30, 2009.

PRESENTATIONS

Suicide and Depression. Spanish American Medical Society, New York, NY, October 5, 1989

A Comparison Study of Patients with Bipolar Disorder and Schizophrenia vs. Normal Controls Utilizing SPECT; presented to the Department of Psychiatry, St. Vincent's Hospital and Medical Center, New York, NY, April 10, 1990

Seclusion and Restraint on a Child Inpatient Unit; presented to the Department of Psychiatry, St. Vincent's Hospital and Medical Center, New York, NY, April 22, 1992

Prognosis and Outcome in Attention Deficit Hyperactivity Disorder; presented to the Division of Child and Adolescent Psychiatry, New York University Medical Center, New York, NY, February 2, 1993

Attention Deficit Hyperactivity Disorder: Treatment, Prognosis and Outcome; presented at the 17th Interamerican Medical Congress of the Spanish American Medical Society New York, NY

Conduct Disorder: Psychosocial and Psychopharmacological Treatments; presented to the Division of Child and Adolescent Psychiatry, New York University Medical Center, New York, NY , March 9, 1994

Rett Syndrome and Its Variants: Recent Progress; presented to the Department of Psychiatry at the Conference of Child and Adolescent Neuropsychiatry: Recent Advances, University of Goteborg, Goteborg, Sweden, May 15, 1994

Assessment of Aggression; Rett Syndrome; presented to the Division of Child and Adolescent Psychiatry, New York University Medical Center, New York, NY, June 4, 1994

Psychopharmacology in Child and Adolescent Psychiatry; presented to the Department of Psychiatry, New York Medical College, Valhalla, NY, January 5, 1995

A Case of Childhood Onset Schizophrenia; presented to the Department of Psychiatry, St. Vincent's Hospital and Medical Center, New York, NY, May 6, 1995

Sexual Abuse in Children and Adolescents: An Overview; presented to the Department of Pediatrics, St. Vincent's Hospital and Medical Center, New York, NY, June 20, 1996

Attention Deficit Hyperactivity Disorder: Prognosis and Outcome; presented to the Division of Child and Adolescent Psychiatry, New York University Medical Center, New York, NY, May 3, 1995

Attention Deficit Hyperactivity Disorder; presented to the Department of Rehabilitation Medicine, St. Vincent's Hospital and Medical Center, New York, NY, September 11, 1995 Psychopharmacology in Selected Child and Adolescent Disorders; presented to the Department of Psychiatry, Metropolitan Hospital, New York, NY, November 18, 1995

Sexual Abuse in Children and Adolescents: An Overview; presented to the Department of Psychiatry, St. Vincent's Hospital and Medical Center, New York, NY, January 13, 1996

Disruptive Behavior Disorders in Adolescents: An Overview ; presented to the Department of Psychiatry, St. Vincent's Hospital and Medical Center, Harrison, NY, March 4, 1996

Carbamazepine Treatment of Conduct Disorder in Children; presented to the Department of Psychiatry, St.Vincent's Hospital and Medical Center, New York, NY, September 23, 1996

Conduct Disorder; presented at the Quaterly Meeting of Guidance Couselors, District 8, Bronx, NY, November 10, 1997

ADHD; Treatment, Prognosis and Outcome; presented to District 2 Guidance Counselors, St. Vincent's Hospital and Medical Center, New York, NY, December 13, 1997

Depression and Bipolar Disorder in Adolescents.; presented to the Division of Child & Adolescent Psychiatry, Westchester Medical Center, Valhalla, NY, April 7, 1998

First Annual APA Update, Sponsored by Pfizer; presented to Psychiatry Attendings, New York, NY, June 3, 1998

Medication Management of Aggression and Conduct Disorders in Children and Adolescents; Course: Clinical Pediatric Psychopharmacology- State of the Art. Sponsored by: Albert Einstein College of Medicine and Montefiore Hospital, New York, NY, September 4, 1998

Depression in Children and Adolescents; presented to Psychiatrists: Sponsored by Pfizer Pharmaceutical Inc., November 19, 1998

Mood Disorders in Adolescents; presented to the Department of Psychiatry, Brookdale Hospital, Brooklyn, NY, January 19, 1999

Conduct Disorder/Aggression; presented to the Psychiatry Department, St. Vincent’s Hospital and Medical Center, New York, NY, June 10, 1999

Schizophrenia in Children and Adolescents; presented to the League School, Brooklyn, NY, November 6, 2001

PTSD after 9/11; presented to CUNY Guidance Counselors, New York, NY, October 2001

"After September 11: Are Provider’s Needs Forgotten?" presented to the Prevent Child Abuse- New York City, February 6, 2002

Early Onset Schizophrenia, presented to New York Council of Adolescent Psychiatry- New York City, May 11, 2002

Panel on Teen Violence Prevention, presented to City Lights Youth Theatre, New York City, February 1, 2006

Driven to the Edge: Self-Injury in Adolescents, presented to NYA of School Nurses, Tarrytown, NY, August 2006

MEETINGS FACILITATED

Regional Consultant Initiative, sponsored by Pfizer Inc., New York, NY, November 6, 1999
Regional Consultant Initiative, sponsored by Pfizer Inc., New York, NY, April 27-28, 2002

COURSES

1. Statistics:

2. Psychoanalytic Psychotherapy (by training and senior analysts of Columbia University Psychoanalytic Institute), February 5, 1996- February 1997 (meets weekly).
3. Child Psychopharmacology (course given by the Department of Psychiatry, Harvard University), March 16-18, 1998.
4. Psychopharmacology in Practice: Clinical and Research Update, 1999, presented by the Foundation for Advanced Education in the Sciences Inc. at the NIMH, Bethesda, Washington DC, November 12-13, 1999.

WEEKLY GRAND ROUNDS ATTENDED

1. Grand Rounds, Department of Psychiatry, St. Vincent's Hospital and Medical Center, New York, NY, 1994-August 2002
2. Grand Rounds, Department of Psychiatry, Division of Child and Adolescent Psychiatry, St. Vincent's Hospital and Medical Center, New York, NY, 1994-1996 (no longer given as separate Ground Rounds)
3. Grand Rounds, Department of Psychiatry, Division of Child and Adolescent Psychiatry, Psychiatric Institute, Columbia University, New York, NY, August 2002-Present

SEMINARS ATTENDED AT NEW YORK UNIVERSITY MEDICAL CENTER

1. Pediatric Psychopharmacology Seminar Department of Psychiatry, Division of Child and Adolescent Psychiatry (Magda Campbell M.D.), Fall 1992-Spring 1994.
2. Principles of Ethical Scientific Conduct: Standards for the Responsible Conduct of Research,Department of Psychiatry, Division of Child and Adolescent Psychiatry (Magda Campbell M.D.), Winter 1992-Spring 1994.
3. Director's Seminar (Research Methodology and Psychopathology), Department of Psychiatry, Division of Child and Adolescent Psychiatry (Magda Campbell M.D.), Fall 1992-Spring 1993; Fall 1993-Spring 1994.
4. Child and Adolescent Psychiatric Epidemiology Seminar, Department of Psychiatry, Division of Child and Adolescent Psychiatry (James Brasic M.D.), Winter 1993-Spring 1993.
5. Research Methods and Procedures Seminar, Department of Psychiatry, Division of Child and Adolescent Psychiatry (Lowell T. Anderson Ph.D.), Fall 1992-Spring 1993; Winter 1994-Summer 1994.
6. Behavioral Genetics Seminar, Department of Psychiatry, Division of Child and Adolescent Psychiatry (J. Gerald Young M.D.), Winter 1993; Spring 1994.

WORKSHOPS ATTENDED AT NEW YORK UNIVERSITY MEDICAL CENTER

1. Workshop on the Overt Aggression Scale (OAS) (by Jonathan Silver M.D.), May 19, 1992.
2. Diagnostic Interview for Children and Adolescents (DICA) Workshop (by W. Reich Ph.D.), June 1-2, 1992.
3. SADS and FH-RDC Workshop (by Jo E. Loth), August 11 and 18, 1992.
4. Rater Assessment Training (BPRS, SANS, SAPS, HAM-D AND GAS) (by Gretchen Hass Ph.D.), August 12-13, 1993.
5. Workshop on the Overt Aggression Scale (OAS) (by Vivian Kafantaris M.D.), September 30, 1992.
6. Rater Training on the Schedule Clinical Interview for DSM-III-R (SCID) (by Miriam Gibbon), October 4 and 6, 1993.

OTHER WORKSHOPS ATTENDED

1. Autism Diagnostic Interview and Autism Diagnostic Observation Schedule (ADI/ADOS) training course, University of Greensboro, NC, November 2-6, 1992.
2. The Statistical Package for
the Social Sciences (SPSS); Introduction to SPSS. Given at the Academic Computing Facility of New York University, February 25, 1994.
3. 4 Day Externship in Emotionally Focused Couples’ Therapy with Sue Johnson, Ackerman Institute, June 27-30, 2011.

SYMPOSIA ATTENDED

1. Bipolar Disorder Across the Life Cycle. Sponsored by the New York Council on Child and Adolescent Psychiatry, New York, NY, April 4, 1998.
2. Gender and Depression: Perspectives for the New Millenium. Sponsored by the Partnership for Women’s Health at the College of Physicians and Surgeon of Columbia University, New York city, NY, April 30 – May 1, 1998.

NATIONAL MEETINGS ATTENDED

1. American Psychopathological Association, Annual Meeting, "New Genetic Approaches to Mental Disorders", New York, NY, March 5-7, 1992.
2. American Academy of Child and Adolescent Psychiatry, 38th Annual Meeting, Washington, DC, October,1992.
3. American College of Neuropsychopharmacology, Annual Meeting, San Juan, PR, December 14-18, 1992.
4. American Academy of Child and Adolescent Psychiatry, 40th Annual Meeting, San Antonio TX, October 26-31, 1993.
5. Association for Research in Nervous and Mental Disease, Annual Meeting, "Biology of Schizophrenia and Affective Disease", New York, NY, December 3-4, 1993.
6, American Psychopathological Association, Annual Meeting, New York, NY March 3-5, 1994.
7. American Psychiatric Associations, 147th Annual Meeting, Philadelphia, PA, May 21-27, 1994.
8. New Clinical Drug Evaluation Unit Program/NCDEU, 34th Annual Meeting, Marco Island, FL, May 31- June 3, 1994.
9. American Academy of Child and Adolescent Psychiatry, 41st Annual Meeting, New York, NY, October 25-30, 1994.
10. American Psychiatric Association, 148th Annual Meeting, Miami, Florida, May 20–25, 1995.
11. American Academy of Child and Adolescent Psychiatry, 43rd Annual Meeting, New Orleans, LA, October 17-22, 1995.
12. American Psychiatric Association, 149th Annual Meeting, New York, NY, May 4-9, 1996.
13. American Psychiatric Association, 150th Annual Meeting, San Diego, CA, May 17-22, 1997.
14. American Academy of Child and Adolescent Psychiatry, 44th Annual Meeting, Toronto, Canada, October 14-19, 1997.
15. American Psychopathological Association, 88th Annual Meeting, Childhood Onset of Adult Psychopathology, New York, NY, March 5-7, 1998.
16. American Psychiatric Association, 151st Annual Meeting, Toronto, Canada May 27 – June 4, 1998.
17. American Academy of Child and Adolescent Psychiatry, 45th Annual Meeting, New Orleans, LA, October 27-November 1, 1998.
18. The Association for the Research in Nervous and Mental Disease; “The Neurobiology of Psychiatry”: 78th Annual Meeting, New York, NY, December 4-5, 1998.
19. American Psychiatric Association, 157th Annual Meeting, New York, NY, May 1-6, 2004

INTERNATIONAL MEETINGS ATTENDED

1. First International Congress on Hormones, Brain and Neuropsychopharmacology, Rhodes, Greece, September 13-17, 1993.
2. Recent Advances in Child and Adolescent Neuropsychiatric Research, University of Goteborg, Goteborg, Sweden, May 16-17, 1994.
3. Health Care Delivery System in France, Louis Pasteur Institute, Paris, France, May 4-8, 1998.

top

Experience, Compassion and Excellence in Psychiatric Care

Curriculum Vitae: Jeanette Eulalia Cueva, M.D.